Crestbridge Increases Global Funds Proposition With Luxembourg Funds Administration Licence
3.12.2019 14:56:00 EET | Business Wire | Press release
Crestbridge has been granted a funds administration licence in Luxembourg in a move that significantly bolsters the company’s capabilities in the jurisdiction and its multijurisdictional proposition for alternative fund managers.
Granted by Luxembourg’s financial services regulator, the Commission de Surveillance du Secteur Financier (CSSF), the new licence enables Crestbridge to provide a broad range of fund administration services from Luxembourg, complementing the well-established Management Company (ManCo) solution already provided from the jurisdiction.
Crestbridge established its ManCo in Luxembourg in 2011 and was one of the first businesses to establish an AIFM in early 2014, providing a third-party management company solution for managers of both UCITS and alternative investment funds with pan-European distribution needs. The business is also one of the only third-party management companies in Luxembourg to hold a European Venture Capital (EuVECA) licence.
The new funds licence also enhances the businesses capability to offer multijurisdictional and bespoke solutions for fund managers, encompassing fund administration, accounting, regulatory and governance solutions, through its dedicated teams of private equity and real assets specialists and network of offices in Jersey, London, Bahrain, and the Cayman Islands as well as Luxembourg. Crestbridge, as a Group, currently services assets valued at in excess of US$120bn.
Commenting on the new licence, Michael Johnson, Group Head of Fund Services at Crestbridge, said: “This is another key step in our growth strategy as we look to build on our excellent track-record of delivering a high quality, solution-driven service for fund managers across a full range of structures and asset classes. Luxembourg is a major hub for alternative asset fund structuring and, particularly with the changing political landscape, this new licence will be a strong addition to our proposition of providing services in key domiciles and enable us to provide a holistic, bespoke and flexible service to managers wanting EU investor access.”
Daniela Klasén-Martin, Group Head of Management Company Services, Managing Director Luxembourg at Crestbridge, added: “Over the past decade, we’ve seen consistent growth in our Management Company business, which can cater for all categories of assets. It’s a model that clearly works for fund managers, offering a straightforward and cost-effective solution to marketing into multiple EU member states, with its appeal really accelerating in light of ongoing political events. Our new funds administration licence, a strategic decision supporting the demands of our existing multijurisdictional Group clients, adds significantly to our existing proposition in Luxembourg, complementing our Management Company solution, which will continue to be independent and an open architecture platform.”
Ends.
Notes to editors
- We are a leading global administration, accounting, management & corporate governance solutions business.
- We provide a broad range of outsourced fiduciary, administrative, accounting and compliance services globally – our expertise spans services, asset classes and jurisdictions. Since 1998, we have been putting our insight and experience to work for clients who include leading corporations, sovereign wealth funds, investor groups, asset managers and ultra-high net worth families.
- Crestbridge employs over 300 people and has five international offices: Bahrain, Cayman Jersey, London, Luxembourg and New York.
- We are regulated in all our locations (see here for more details)
Follow us
https://www.linkedin.com/company/crestbridge?trk=nav_account_sub_nav_company_admin
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191203005537/en/
Contact information
Daniel Beurthe
Account Executive, Peregrine Communications
Daniel.beurthe@peregrinecommunications.com
+44 (0) 203 040 0876,
or
Nicola Nicholson,
Head of Marketing at Crestbridge
tel. +44 (0) 1534 835014
e-mail nicola.nicholson@crestbridge.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FERM FOOD Acquires Orkla’s Former Site and Scales Up: Up to 20,000 Tonnes of Fermented Ingredients Per Year11.3.2026 08:00:00 EET | Press release
Danish ingredient producer FERM FOOD is acquiring Orkla’s former manufacturing site in Skovlund, Denmark, effective 1 April 2026. The acquisition provides new production facilities to expand the output of fermented plant-based ingredients for the food industry — driven by export demand that has emerged faster than expected. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310904877/en/ Jens Legarth (CEO), Rikke Matthiesen (CSO), and Torbjørn Tyndkjær-Thomsen (Food & Process Developer) at FERM FOOD’s new production facilities. “We have outgrown our current facilities. With the Skovlund site, we can supply many more food manufacturers in Denmark and abroad. Global interest has developed faster than we expected — and that is why we are scaling up now,” says Jens Legarth, CEO of FERM FOOD. Once fully ramped up, the new fermentation facility is expected to reach an annual capacity of up to 20,000 tonnes, depending on product mix
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for future use in connection with Galderma's employe
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 08:00:00 EET | Press release
As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/en/ SkyDefender © Thales Thales SkyDefender provides full protection against all types of air threats, from a few kilometres to several thousands of kilometres: Short-range: for protection of forces, vital assets and sensitive sites: ForceShield creates a real protection bubble against lower layer and surface threats at very short- and short-range, such as drones. Medium-range: for protection at theatre-level defence: SAMP-T NG by eurosam1 with up to 150 km engagement range, including Thales’ powerful Ground Fire radar with 350 km range and 360°/90° coverage against medium-range defence. Long-range: for protection against long-range threats with early-warning capabilities: a unique capacity
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 08:00:00 EET | Press release
Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rights to develop and commercialize corticorelin for the treatment of peritumoral brain edema (PTBE) in Japan. PTBE is a tumor-associated condition for which no approved targeted therapies currently exist. Neupharma will finance and conduct a pivotal clinical trial in Japan to support filing for approval in Japan. Curatis will receive upfront and milestone payments for the achievement of regulatory and commercial targets totaling up to CHF 83.5 million, as well as royalties on future sales in Japan of up to 20%. The agreement stipulates that corticorelin is planned to be introduced in Japan initially for children and adolescents. A meeting with
Galderma Completes Successful Placement of EUR 500 Million Eurobond11.3.2026 07:55:00 EET | Press release
Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche EUR 500 million Eurobond. The bond has a 5-year maturity and carries a fixed-rate annual coupon of 3.375%. The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026, and will be listed on the SIX Swiss Exchange. Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction. Net proceeds from the transaction will be used to fully repay Galderma’s existing bank term loan issued in connection with the company’s initial public offering in March 2024. The transaction represents the final step in Galderma’s refinancing process, having obtained two investment grade credit ratings. Galderma is currently rated ‘BBB’ (stable outlook) by Fitc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
